Stefan Dirnhofer - Genetic Mutations

Author Information

Stefan Dirnhofer is affiliated with the Institute of Medical Genetics and Pathology at the University Hospital Basel, located in Basel, Switzerland. His research primarily focuses on pathology and genetics, contributing significantly to the understanding and management of various hematologic and oncologic conditions.

Research Contributions

Stefan Dirnhofer's research spans a wide array of topics within pathology and genetics. His recent work includes the identification of reliable markers for acute monocytic leukemias, the integration of baseline metabolic parameters and mutational profiles to predict outcomes in diffuse large B-cell lymphoma (DLBCL) patients, and the management of transthyretin amyloidosis. His studies have also explored the mutational landscape of marginal zone B-cell lymphomas and the role of RNA sequencing in diagnosing NUT carcinoma. Additionally, Dirnhofer has contributed to understanding the transcriptional programs controlled by OBF1 and Oct factors in germinal centers.

Aliases

S Dirnhofer, S. Dirnhofer, Stefan Dirnhofer

Publication and Citation Metrics

Metric	Value
Citation Count	2548
H-index	25
Paper Count	132

Publications:

IRF8 Is a Reliable Monoblast Marker for Acute Monocytic Leukemias, But Does Not Discriminate Between Monoblasts and Plasmacytoid Dendritic Cells.

DOI: 10.1097/PAS.0000000000001874

Year: 2022

Integration of Baseline Metabolic Parameters and Mutational Profiles Predicts Long-Term Response to First-Line Therapy in DLBCL Patients: A Post Hoc Analysis of the SAKK38/07 Study

DOI: 10.3390/cancers14041018

Year: 2022

Management of transthyretin amyloidosis.

DOI: 10.4414/smw.2021.w30053

Year: 2021

INTEGRATION OF BASELINE METABOLIC PARAMETERS AND MUTATIONAL PROFILE PREDICTS OUTCOME IN DLBCL PATIENTS. A POST HOC ANALYSIS OF SAKK38/07 STUDY

DOI: 10.1002/hon.18_2879

Year: 2021

DEVELOPMENT AND VALIDATION OF A PET RADIOMICS PROGNOSTIC MODEL FOR DIFFUSE LARGE B CELL LYMPHOMA

DOI: 10.1002/hon.22_2879

Year: 2021

Management of transthyretin amyloidosis Guidelines from the 1st Swiss Amyloidosis Network (SAN) Consensus conference

DOI:

Year: 2021

NUT Carcinoma: A Clinical, Morphological and Immunohistochemical Mimicker—The Role of RNA Sequencing in the Diagnostic Procedure

DOI: 10.1177/10668969211047981

Year: 2021

Blast counts are lower in the aspirate as compared to trephine biopsy in acute myeloid leukemia and myelodysplastic syndrome expressing CD56

DOI: 10.1111/ijlh.13508

Year: 2021

MUTATIONAL LANDSCAPE OF MARGINAL ZONE B‐CELL LYMPHOMAS OF VARIOUS ORIGIN: ORGANOTYPIC ALTERATIONS AND DIAGNOSTIC POTENTIAL FOR ASSIGNMENT OF ORGAN ORIGIN

DOI: 10.1002/hon.17_2880

Year: 2021

OBF1 and Oct factors control the germinal center transcriptional program.

DOI: 10.1182/blood.2020010175

Year: 2021

What Are the Common PARP Inhibitors?

How is Cellular Heterogeneity Studied?

What are Genetic Disorders?

How Can Hemophilia Be Managed?

What are the Evolutionary Implications of Synonymous Codons?

What is the Role of Epigenetics in Mutations?

Can Neutral Mutations Become Beneficial or Harmful?

What is a Substitution Mutation?

Can Genetic Mutations Be Treated or Prevented?

What Causes Cellular Heterogeneity?

Partnered Content Networks

Relevant Topics